Oncolytics Biotech (ONCY) Deferred Taxes (2009 - 2010)

Oncolytics Biotech (ONCY) posted quarterly Deferred Taxes of -$22000.0 for Q4 2010, down 101.97% quarter-over-quarter from $1.1 million in Q3 2010.

Oncolytics Biotech (ONCY) Deferred Taxes (2009 - 2010) Analysis & Trends

Oncolytics Biotech (ONCY) has reported Deferred Taxes for 2 consecutive years, with -$22000.0 the latest figure, recorded in Q4 2010.

In Q4 2010, Deferred Taxes changed N/A year-over-year to -$22000.0; the TTM figure through Dec 2010 stood at $3.3 million (changed N/A YoY), while the FY2010 annual figure was $1.1 million, changed N/A from the prior year.
Deferred Taxes retreated to -$22000.0 in Q4 2010 per ONCY's latest filing, from $1.1 million in the prior quarter.
Across five years, Deferred Taxes topped out at $1.1 million in Q1 2010 and bottomed at -$1.1 million in Q1 2009.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Deferred Taxes (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-69.70 Mn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	194.40 Mn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	2.66 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-
10	Oncolytics Biotech	96.23 Mn	96.23 Mn	-	-

Download Data